search
Back to results

Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients (BRIDION)

Primary Purpose

Morbidly Obese Patients

Status
Completed
Phase
Phase 2
Locations
Belgium
Study Type
Interventional
Intervention
Sugammadex 2 mg/kg
Sugammadex. 4 mg/kg
Neuromuscular monitoring.
Clinical evaluation of residual curarization .
Sponsored by
University Hospital, Ghent
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Morbidly Obese Patients

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria :

  • ASA I-II-III
  • Age 18 - 65 year
  • Male or female
  • BMI > 30

Exclusion criteria :

  • Renal failure
  • Liver dysfunction
  • Breastfeeding female patients, or female patients without reliable contraception
  • Neuromuscular disease
  • Malignant hyperthermia or a family history of malignant hyperthermia
  • Allergy for neuromuscular blocking agents or other medications used during general anesthesia
  • Infectious disease or patients with fever
  • Patients who already received rocuronium or sugammadex on the day of the study

Sites / Locations

  • Ghent University Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

BMI < 50, Total Body Weight (TBW), 2mg/kg

BMI < 50, TBW, 4 mg/kg

BMI < 50, Ideal Body Weight (IBW), 2 mg/kg

BMI < 50, IBW, 4 mg/kg

BMI > 50, TBW, 2mg/kg

BMI > 50, TBW, 4mg/kg

BMI >50, IBW, 2 mg/kg

BMI >50, IBW, 4 mg/kg

Arm Description

Patients with a BMI < 50, who will be dosed according to total body weight.

Patients with a BMI < 50, who will be dosed according to total body weight.

Patients with a BMI < 50, who will be dosed according to ideal body weight.

Patients with a BMI < 50, who will be dosed according to ideal body weight.

Patients with a BMI > 50, who will be dosed according to total body weight.

Patients with a BMI > 50, who will be dosed according to total body weight.

Patients with a BMI > 50, who will be dosed according to ideal body weight.

Patients with a BMI > 50, who will be dosed according to ideal body weight.

Outcomes

Primary Outcome Measures

Time to complete recovery of muscle relaxation, 30 minutes after end of surgery.
Measured with TOF Watch SX (TOF ratio > 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.
Time to complete recovery of muscle relaxation, 1 hour after the end of surgery.
Measured with TOF Watch SX (TOF ratio > 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.
Time to complete recovery of muscle relaxation, 1 hour 30 minutes after the end of surgery.
Measured with TOF Watch SX (TOF ratio > 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.
Time to complete recovery of muscle relaxation, 2 hours after the end of surgery.
Measured with TOF Watch SX (TOF ratio > 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.

Secondary Outcome Measures

Need/use of rescue medication at the end of surgery
Additional administration of sugammadex 2 mg/kg Total Body Weight) at the end of surgery.

Full Information

First Posted
July 23, 2013
Last Updated
July 7, 2021
Sponsor
University Hospital, Ghent
search

1. Study Identification

Unique Protocol Identification Number
NCT01911520
Brief Title
Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients
Acronym
BRIDION
Official Title
Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Ghent

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
During laparoscopic bariatric surgery, adequate muscle relaxation is important to maintain good surgical conditions. To achieve this muscle relaxation, neuromuscular transmission blocking agents, such as rocuronium (Esmeron®) are used. It sometimes happens that there is still some neuromuscular blocking activity left in the patient on awakening from anesthesia. This is called residual curarization and is known to cause postoperative complications such as impairment of respiratory function. Sugammadex (Bridion®) is a novel drug which selectively binds rocuronium (Esmeron®). It allows for reversing of neuromuscular transmission blocking activity. Until now, all studies with sugammadex were performed in non-obese patients. Obese patient have a high risk to suffer from post-operative respiratory failure. Therefore it is vital to avoid residual curarization. Sugammadex might be an important factor. Obese patients have a large total body weight different from ideal body weight. Recent research demonstrated that the dose for the neuromuscular blocking agent rocuronium (Esmeron®) needs to be calculated on the patients' Ideal Body Weight rather than on Total Body Weight. At this moment no data is available on the dose-response relationship of sugammadex in morbidly obese patients. We hypothesize that in morbidly obese patients sugammadex should be dosed on ideal bodyweight, instead of total bodyweight.
Detailed Description
Flowchart : 72 participants Stratification BMI<50 BMI >50 Randomization Randomization TBW IBW TBW IBW 2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 2mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9 4mg/kg n=9 TBW : Total Body Weight IBW : Ideal Body Weight

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Morbidly Obese Patients

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BMI < 50, Total Body Weight (TBW), 2mg/kg
Arm Type
Experimental
Arm Description
Patients with a BMI < 50, who will be dosed according to total body weight.
Arm Title
BMI < 50, TBW, 4 mg/kg
Arm Type
Experimental
Arm Description
Patients with a BMI < 50, who will be dosed according to total body weight.
Arm Title
BMI < 50, Ideal Body Weight (IBW), 2 mg/kg
Arm Type
Experimental
Arm Description
Patients with a BMI < 50, who will be dosed according to ideal body weight.
Arm Title
BMI < 50, IBW, 4 mg/kg
Arm Type
Experimental
Arm Description
Patients with a BMI < 50, who will be dosed according to ideal body weight.
Arm Title
BMI > 50, TBW, 2mg/kg
Arm Type
Experimental
Arm Description
Patients with a BMI > 50, who will be dosed according to total body weight.
Arm Title
BMI > 50, TBW, 4mg/kg
Arm Type
Experimental
Arm Description
Patients with a BMI > 50, who will be dosed according to total body weight.
Arm Title
BMI >50, IBW, 2 mg/kg
Arm Type
Experimental
Arm Description
Patients with a BMI > 50, who will be dosed according to ideal body weight.
Arm Title
BMI >50, IBW, 4 mg/kg
Arm Type
Experimental
Arm Description
Patients with a BMI > 50, who will be dosed according to ideal body weight.
Intervention Type
Drug
Intervention Name(s)
Sugammadex 2 mg/kg
Intervention Description
Patients receive 2 mg/kg Sugammadex.
Intervention Type
Drug
Intervention Name(s)
Sugammadex. 4 mg/kg
Intervention Description
Patients receive 4 mg/kg Sugammadex.
Intervention Type
Procedure
Intervention Name(s)
Neuromuscular monitoring.
Intervention Description
Neuromuscular monitoring using a TOF watch SX (Organon).
Intervention Type
Procedure
Intervention Name(s)
Clinical evaluation of residual curarization .
Intervention Description
Every 30 min, during the first 2 hours after the end of the surgery.
Primary Outcome Measure Information:
Title
Time to complete recovery of muscle relaxation, 30 minutes after end of surgery.
Description
Measured with TOF Watch SX (TOF ratio > 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.
Time Frame
30 minutes after end of surgery.
Title
Time to complete recovery of muscle relaxation, 1 hour after the end of surgery.
Description
Measured with TOF Watch SX (TOF ratio > 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.
Time Frame
1hour after end of surgery.
Title
Time to complete recovery of muscle relaxation, 1 hour 30 minutes after the end of surgery.
Description
Measured with TOF Watch SX (TOF ratio > 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.
Time Frame
1hour 30 minutes after end of surgery.
Title
Time to complete recovery of muscle relaxation, 2 hours after the end of surgery.
Description
Measured with TOF Watch SX (TOF ratio > 0.9); clinical evaluation (eg head lift) of residual curarization in the Post Anesthetic Care.
Time Frame
2 hours after end of surgery.
Secondary Outcome Measure Information:
Title
Need/use of rescue medication at the end of surgery
Description
Additional administration of sugammadex 2 mg/kg Total Body Weight) at the end of surgery.
Time Frame
The hours following the end of surgery.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria : ASA I-II-III Age 18 - 65 year Male or female BMI > 30 Exclusion criteria : Renal failure Liver dysfunction Breastfeeding female patients, or female patients without reliable contraception Neuromuscular disease Malignant hyperthermia or a family history of malignant hyperthermia Allergy for neuromuscular blocking agents or other medications used during general anesthesia Infectious disease or patients with fever Patients who already received rocuronium or sugammadex on the day of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jurgen Van Limmen, MD
Organizational Affiliation
University Hospital, Ghent
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Luc De Baerdemaeker, MD, PhD
Organizational Affiliation
University Hospital, Ghent
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Koen Reyntjens, MD
Organizational Affiliation
University Hospital, Ghent
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ghent University Hospital
City
Ghent
ZIP/Postal Code
9000
Country
Belgium

12. IPD Sharing Statement

Links:
URL
http://www.uzgent.be
Description
Related Info

Learn more about this trial

Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients

We'll reach out to this number within 24 hrs